|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
379231-04-6
|
|
gptkbp:clinicalTrialPhase
|
Phase II
NCT01864655
NCT02167256
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:hasMolecularFormula
|
C22H17ClFN5O3S
|
|
gptkbp:hasSMILES
|
COC1=CC(=C(C=C1Cl)N2C=NC(=NC2)NC3=CC=CC=C3)N4CCN(CC4)C5=CC=CC=C5S(=O)(=O)N
|
|
gptkbp:hasUNII
|
2XJ0GDN6YW
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
saracatinib
|
|
gptkbp:indication
|
gptkb:cancer
Alzheimer's disease (investigational)
|
|
gptkbp:isInvestigational
|
true
|
|
gptkbp:IUPACName
|
4-(2-(6-chloro-2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-ylamino)phenyl)benzenesulfonamide
|
|
gptkbp:legalStatus
|
patented
|
|
gptkbp:mechanismOfAction
|
Src kinase inhibitor
Abl kinase inhibitor
|
|
gptkbp:molecularWeight
|
485.92 g/mol
|
|
gptkbp:PubChem_CID
|
10127622
8290227
CHEMBL479471
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
AZD0530
|
|
gptkbp:target
|
gptkb:Src_family_kinases
Abl kinase
|
|
gptkbp:bfsParent
|
gptkb:Src_family_kinases
gptkb:ZD4522
|
|
gptkbp:bfsLayer
|
7
|